Servotech Pharma Impex Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-07-2024
- Paid Up Capital ₹ 0.10 M
as on 31-07-2024
- Company Age 31 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue -41.13%
(FY 2023)
- Profit -79.53%
(FY 2023)
- Ebitda 101.13%
(FY 2023)
- Net Worth 1.16%
(FY 2023)
- Total Assets -53.32%
(FY 2023)
About Servotech Pharma Impex
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Ramchand, Tarana Suresh, and Meena Naidu serve as directors at the Company.
- CIN/LLPIN
U51109MH1993PTC074345
- Company No.
074345
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Servotech Pharma Impex Private Ltd offer?
Servotech Pharma Impex Private Ltd offers a wide range of products and services, including Dried Chillies & Pepper, Dry Red Chilli, Industrial Minerals, Bentonite, Oil Seeds, Sesame Seed, Industrial Acid, Hydrochloric Acid, Industrial Chemicals & Supplies, Water Treatment Chemicals.
Who are the key members and board of directors at Servotech Pharma Impex?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Ramchand  | Director | 05-Oct-1993 | Current |
| Tarana Suresh | Director | 01-Sep-2012 | Current |
| Meena Naidu | Additional Director | Current |
Financial Performance and Corporate Structure Insights of Servotech Pharma Impex.
Servotech Pharma Impex Private Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.13% decrease. The company also saw a substantial fall in profitability, with a 79.53% decrease in profit. The company's net worth moved up by a moderate rise of 1.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Servotech Pharma Impex?
In 2023, Servotech Pharma Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Servotech Pharma Impex?
Unlock and access historical data on people associated with Servotech Pharma Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Servotech Pharma Impex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Servotech Pharma Impex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
